![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
HuiGene Therapeutics
Company Type: Therapeutics
Main focus: Development of therapeutics based on RNA-editing tools (CRISPR/Cas) and delivery via adeno-associated virus (AAV)
Company stage: Pre-clinical
Diseases: Ophthalmology, central nervous system, muscle dystrophies, otology (ear), hepatology
Genome-editing tool: CRISPR/Cas-based RNA-editing tools
Funding stage: Series C
Location: Pudong New Area, Shangai
Website: www.huidagene.com/en/
Pipeline: www.huidagene.com/en/goods/pipeline.html
Partners:
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Huigene_67921564de_22f3769244.jpg)
HuiGene Therapeutics is a pre-clinical stage company with multiple R&D pipelines for ophthalmology, neurology, otology, myology and hepatology. The company aims to treat genetic conditions – including rare diseases – via CRISPR-Cas-based RNA-editing tools and adeno-associated virus (AAV) delivery vectors. Their pre-clinical studies are supported by an in-house facility focused on generating CRISPR-edited animal models to showcase the efficacy of their therapeutics.